Expertise in
17
conditions

Dr. Ignacio Garrido

Oncology
85 N Medical Dr, 
Salt Lake City, UT 
Accepting New Patients
Offers Telehealth
Expertise in
17
conditions
85 N Medical Dr, 
Salt Lake City, UT 

Overview

Ignacio Garrido is an Oncologist practicing medicine in Salt Lake City, Utah.

Dr. Garrido is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Pancreatic Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Pancreatoblastoma, and Pancreatectomy.

Dr. Garrido is board certified in American Board Of Internal Medicine. He is actively involved in clinical research, co-authoring 111 peer reviewed articles and participating in 21 clinical trials. Dr. Garrido is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in UT

Board Certifications

American Board Of Internal Medicine

Hospital Affiliations

University Of Utah Hospital And Clinics

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BridgeSpan
  • EPO
  • HMO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Mountain Health
  • OTHER COMMERCIAL
  • POS
  • PPO
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Regence
  • EPO
  • PPO
SelectHealth
  • HMO
  • POS
Steward Health Care
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
University of Utah Health
  • EPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

Hematology-oncology - Nielsen Rehabilitation Hospital
85 N Medical Dr, Salt Lake City, UT 84112
Other Locations
Hematology-oncology - Hci Hem-onc Clinic
1950 Circle Of Hope Dr, Salt Lake City, UT 84112

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

17 Clinical Trials

Exceptional Responders Pilot Study: Molecular Profiling of Tumors From Cancer Patients Who Are Exceptional Responders
Exceptional Responders Pilot Study: Molecular Profiling of Tumors From Cancer Patients Who Are Exceptional Responders
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other
Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients With Germline BRCA1 or BRCA2 Mutations
Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients With Germline BRCA1 or BRCA2 Mutations
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Procedure, Drug, Biological
Study Drugs: Olaparib, Pembrolizumab
Study Phase: Phase 2
A Phase I Study of Anetumab Ravtansine in Combination With Either Anti-PD-1 Antibody, or Anti-CTLA4 and Anti-PD-1 Antibodies or Anti-PD-1 Antibody and Gemcitabine in Mesothelin-Positive Advanced Pancreatic Adenocarcinoma
A Phase I Study of Anetumab Ravtansine in Combination With Either Anti-PD-1 Antibody, or Anti-CTLA4 and Anti-PD-1 Antibodies or Anti-PD-1 Antibody and Gemcitabine in Mesothelin-Positive Advanced Pancreatic Adenocarcinoma
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Biological, Procedure, Drug
Study Drugs: Anetumab ravtansine, Gemcitabine hydrochloride, Ipilimumab, Nivolumab
Study Phase: Phase 1
A Phase I/II Study of Indoximod in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Adenocarcinoma of the Pancreas
A Phase I/II Study of Indoximod in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Adenocarcinoma of the Pancreas
Enrollment Status: Completed
Publish Date: April 03, 2026
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Enrollment Status: Active_not_recruiting
Publish Date: March 06, 2026
Intervention Type: Drug
Study Drug: Entrectinib
Study Phase: Phase 2
Randomized Phase II Study of 2nd Line FOLFIRI Versus Modified FOLFIRI With PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer
Randomized Phase II Study of 2nd Line FOLFIRI Versus Modified FOLFIRI With PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 05, 2026
Intervention Type: Drug, Other
Study Drugs: Fluorouracil, Irinotecan Hydrochloride, Leucovorin Calcium, Veliparib
Study Phase: Phase 2
A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
Enrollment Status: Completed
Publish Date: January 12, 2026
Intervention Type: Drug
Study Drugs: Cisplatin, Gemcitabine, Nab-Paclitaxel
Study Phase: Phase 3
A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Enrollment Status: Terminated
Publish Date: October 21, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Phase 1/1b Study of the Safety of TTX-030 as a Single Agent and in Combination With Pembrolizumab or Chemotherapy in Patients With Lymphoma or Solid Tumor Malignancies
Phase 1/1b Study of the Safety of TTX-030 as a Single Agent and in Combination With Pembrolizumab or Chemotherapy in Patients With Lymphoma or Solid Tumor Malignancies
Enrollment Status: Completed
Publish Date: July 02, 2025
Intervention Type: Drug
Study Drugs: TTX-030, Pembrolizumab, Docetaxel, Gemcitabine, Nab-Paclitaxel
Study Phase: Phase 1
A Phase I, First-in-human, Open-label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP 1454
A Phase I, First-in-human, Open-label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP 1454
Enrollment Status: Completed
Publish Date: May 01, 2025
Intervention Type: Drug
Study Drugs: TP-1454 Alone, TP-1454 Combination Therapy
Study Phase: Phase 1
View 9 Less Clinical Trials

91 Total Publications

Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multi-Selective Inhibitors in NRAS-Mutated Melanoma.
Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multi-Selective Inhibitors in NRAS-Mutated Melanoma.
Journal: bioRxiv : the preprint server for biology
Published: December 25, 2025
Similar Doctors
Expertise in
17
conditions
Dr. Neeraj Agarwal
Oncology
Expertise in
17
conditions
Dr. Neeraj Agarwal
Oncology

Huntsman Cancer Institute, Hematology-Oncology

1950 Circle Of Hope Dr, 
Salt Lake City, UT 
 (0.1 miles away)
801-585-0100
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Neeraj Agarwal is an Oncologist practicing medicine in Salt Lake City, Utah. Dr. Agarwal is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Renal Cell Carcinoma (RCC), Familial Prostate Cancer, Orchiectomy, and Tissue Biopsy. Dr. Agarwal is board certified in American Board Of Internal Medicine. Dr. Agarwal is currently accepting new patients.

Expertise in
16
conditions
Dr. Michael Pulsipher
Hematology | Oncology
Expertise in
16
conditions
Dr. Michael Pulsipher
Hematology | Oncology

Pediatric Bone Marrow Transplant

100 N Mario Capecchi Dr, 
Salt Lake City, UT 
 (0.3 miles away)
801-662-4700
Languages Spoken:
English
See accepted insurances

Michael Pulsipher is a Hematologist and an Oncologist practicing medicine in Salt Lake City, Utah. Dr. Pulsipher is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Acute Lymphoblastic Leukemia (ALL), Graft Versus Host Disease (GvHD), Leukemia, Severe Combined Immunodeficiency (SCID), and Bone Marrow Transplant. Dr. Pulsipher is board certified in American Board Of Pediatrics.

Expertise in
7
conditions
Dr. Elizabeth Raetz
Hematology | Oncology
Expertise in
7
conditions
Dr. Elizabeth Raetz
Hematology | Oncology

Pediatric Hematology-Oncology

100 N Mario Capecchi Dr, 
Salt Lake City, UT 
 (0.3 miles away)
801-662-4700
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Elizabeth Raetz is a Hematologist and an Oncologist practicing medicine in Salt Lake City, Utah. Dr. Raetz is highly rated in 7 conditions, according to our data. Her clinical expertise encompasses Acute Lymphoblastic Leukemia (ALL), Leukemia, Adult T-Cell Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Raetz is board certified in American Board Of Pediatrics. Dr. Raetz is currently accepting new patients.

Frequently Asked Questions about Dr. Ignacio Garrido

How do I make an appointment with Dr. Ignacio Garrido?

You can book an appointment with Dr. Ignacio Garrido by calling their office at 801-585-0100. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Ignacio Garrido a top-rated expert for Pancreatic Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Ignacio Garrido is classified as an Elite expert for Pancreatic Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Ignacio Garrido specialize in?

While Dr. Ignacio Garrido is a Oncology, they have specific expertise in Pancreatic Cancer, Colorectal Cancer, and Pancreatic Ductal Adenocarcinoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Ignacio Garrido participate in research or clinical trials?

Yes. Dr. Ignacio Garrido has published 91 articles and abstracts on conditions like Pancreatic Cancer. You can view a list of Dr. Ignacio Garrido's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Ignacio Garrido accept my insurance?

Dr. Ignacio Garrido accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 801-585-0100 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Garrido's expertise for a condition
ConditionClose
View All 10 Advanced Conditions
View All 48 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile